- Home
- LPCN vs APM Comparison
LPCN vs APM Comparison
Compare LPCN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- APM
- Stock Information
- Founded
- LPCN 1997
- APM 2010
- Country
- LPCN United States
- APM United Kingdom
- Employees
- LPCN N/A
- APM N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- APM Health Care
- Exchange
- LPCN Nasdaq
- APM Nasdaq
- Market Cap
- LPCN 18.2M
- APM 18.9M
- IPO Year
- LPCN N/A
- APM 2018
- Fundamental
- Price
- LPCN $2.75
- APM $1.48
- Analyst Decision
- LPCN Strong Buy
- APM
- Analyst Count
- LPCN 1
- APM 0
- Target Price
- LPCN $8.00
- APM N/A
- AVG Volume (30 Days)
- LPCN 59.3K
- APM 337.0K
- Earning Date
- LPCN 11-07-2025
- APM 04-30-2025
- Dividend Yield
- LPCN N/A
- APM N/A
- EPS Growth
- LPCN N/A
- APM N/A
- EPS
- LPCN N/A
- APM N/A
- Revenue
- LPCN $4,208,119.00
- APM N/A
- Revenue This Year
- LPCN N/A
- APM N/A
- Revenue Next Year
- LPCN N/A
- APM N/A
- P/E Ratio
- LPCN N/A
- APM N/A
- Revenue Growth
- LPCN N/A
- APM N/A
- 52 Week Low
- LPCN $2.65
- APM $0.46
- 52 Week High
- LPCN $6.17
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- LPCN 38.39
- APM 40.47
- Support Level
- LPCN $2.75
- APM $1.43
- Resistance Level
- LPCN $2.92
- APM $1.59
- Average True Range (ATR)
- LPCN 0.14
- APM 0.18
- MACD
- LPCN -0.04
- APM -0.03
- Stochastic Oscillator
- LPCN 6.12
- APM 7.62
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.